about
Dietary Protein Sources and Incidence of Breast Cancer: A Dose-Response Meta-Analysis of Prospective StudiesTime for a new language for asthma control: results from REALISE AsiaA multicenter phase II study of the efficacy and safety of docetaxel plus cisplatin in Asian chemonaïve patients with metastatic or locally advanced non-small cell lung cancer.Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts.Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancerImpact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.Expression of aquaporin 5 in primary carcinoma and lymph node metastatic carcinoma of non-small cell lung cancerAsthma in Asia: Physician perspectives on control, inhaler use and patient communications.Development and Validation of an Attitudinal-Profiling Tool for Patients With Asthma.Salvage therapy beyond targeted therapy in lung adenocarcinoma.Lung cancer staging now and in the future.Therapeutic Effects of Herbal Chemicals in Traditional Chinese Medicine on Alzheimer's Disease.Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma.Arsenic trioxide-induced cytotoxicity in small cell lung cancer via altered redox homeostasis and mitochondrial integrity.Downregulation of thymidylate synthase and E2F1 by arsenic trioxide in mesothelioma.E2F1 downregulation by arsenic trioxide in lung adenocarcinoma.Downregulation of thymidylate synthase with arsenic trioxide in lung adenocarcinoma.Combination of arsenic trioxide and chemotherapy in small cell lung cancer.Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy.Capecitabine as salvage treatment for lymphoepithelioma-like carcinoma of lung.Utility of 18F-FDG PET/CT in the assessment of lymphoepithelioma-like carcinoma.Plasma EGFR Mutation Detection Associated With Survival Outcomes in Advanced-Stage Lung Cancer.Tumour growth-suppressive effect of arsenic trioxide in squamous cell lung carcinoma.The Effect of Tumor Microenvironment on Autophagy and Sensitivity to Targeted Therapy in EGFR-Mutated Lung Adenocarcinoma.Control of brain metastases with alectinib in anaplastic lymphoma kinase-rearranged lung cancerInsights, attitudes and perceptions about asthma and its treatment: findings from a multinational survey of patients from 8 Asia-Pacific countries and Hong Kong.Lymphoepithelioma-like carcinoma of the lung in a patient with silicosis.In vitro study of regulation of IL-6 production in bronchiectasis.Genetic predisposition to lung adenocarcinoma among never-smoking Chinese with different epidermal growth factor receptor mutation status.Ciliary central microtubular orientation is of no clinical significance in bronchiectasis.EBUS-TBNA in patients presented with superior vena cava syndrome.Effect of therapeutic arsenic exposure on pulmonary function.Severe acute respiratory syndrome: radiographic evaluation and clinical outcome measures.Risk factors associated with lung cancer in Hong Kong.SUV as an adjunct in evaluating disease activity in idiopathic pulmonary fibrosis - a pilot study.Endobronchial ultrasound for diagnosis of synchronous primary lung cancers.T790M mutant copy number quantified via ddPCR predicts outcome after osimertinib treatment in lung cancer.Recombinant human arginase induces apoptosis through oxidative stress and cell cycle arrest in small cell lung cancer
P50
Q30240889-141EA5CE-CD57-4B0D-A003-D770382BCFDEQ30666462-502B5E8F-5BCC-4ACA-AA1E-53DF369C600EQ33348926-29F1D9A7-547F-4224-9028-B5ADB83A458AQ33408501-7F322534-CA79-4B8F-A34B-C6C115A1E99CQ33630104-6ED88FAA-7795-47CC-AA15-84D52174EDC2Q34159240-2855FB1F-EA99-41B2-A7A4-6C41E59555D5Q34339890-99F02EC6-D50E-4DD5-A743-65A9F81C2132Q35759055-B61DCE38-CF27-47B5-AEBC-D2DEA44EA15CQ35994618-07D4A56C-FFCE-464F-93E5-A2C40FFAC892Q37404873-33B425C0-3B7D-4AB4-BECE-FB53982E92F6Q38164583-59387962-6424-465B-BEC0-4A336C6295F6Q38356020-99B3D603-C7FC-48AC-ACA5-0E9160A13619Q38491762-8D94DC00-FD4E-47FB-AD00-26321C6FDEB7Q38735299-8C2EAD1F-4075-49E6-8DFA-86F723D24B22Q38921986-DDEF9784-2606-4E30-A142-F0A3A3D048C3Q38946061-508A6155-E883-43DE-AB32-6022C09AA061Q38961366-509C0F20-DA8A-42A3-A3DD-B4710F4AC501Q39009220-9CE08E25-0A79-4B93-BAB4-FAF1FF800339Q39095096-0C63BADA-5DEA-44FC-8D07-AF33F997C052Q39139425-1D9FE77F-C3DE-459D-9DBE-AA74930907F6Q39843697-DCD71B73-F6F7-4565-9AC9-82FAE2BD3F4CQ39952672-1E4F7D19-874F-42A4-BA73-6A6C6C3E00FCQ40994180-B4F57394-A860-4E6C-89BF-49E69447F2D0Q41517568-57355198-531B-4263-9319-6A97E4810744Q41614936-CA8B03EA-625B-4B5F-8557-C889F8A8D9CFQ41775545-A37AA6B1-3235-4BE6-B712-F725464B9177Q42318174-E2F455D0-30EF-4CDA-8038-9F5C099332E0Q43752448-4CC7C5D0-1123-4528-B1CD-C5DF3C039E2CQ44571293-8978D8E3-5164-470F-8BE0-760CA79F4D5FQ44835779-9EAC9257-3D75-4B32-B162-31C4DCC4276EQ47700374-2B1F5FEB-583D-4479-AB9D-99C06E3B6DB7Q47843186-28F20109-2E8D-4204-B51F-7DE131BB0E8DQ48168707-31185D3E-3179-4353-A679-7BB52477C2ABQ50851845-0DE6C66F-38CB-40C1-A354-5003ED8FC18BQ51645868-16915780-AB3A-478A-A9B9-B62A24DCCFDBQ51676310-0B225FF5-05D1-4017-ABD1-35B5BB7D454CQ53081638-6962484A-4D14-4BFA-BA3F-967C72F3BAFBQ53407189-4D1CBB8E-52E2-4235-8BF1-E95F74814482Q55361062-6EE82B33-96AD-4B9D-ABB9-BF059C2736E0Q58781169-17509426-E6A0-4FF6-B651-C377CEB39779
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
James Chung-Man Ho
@ast
James Chung-Man Ho
@en
James Chung-Man Ho
@es
James Chung-Man Ho
@nl
type
label
James Chung-Man Ho
@ast
James Chung-Man Ho
@en
James Chung-Man Ho
@es
James Chung-Man Ho
@nl
prefLabel
James Chung-Man Ho
@ast
James Chung-Man Ho
@en
James Chung-Man Ho
@es
James Chung-Man Ho
@nl
P106
P1153
7402649981
P21
P31
P496
0000-0003-4499-5284